The safety of seasonal influenza vaccines in Australian children in 2013

Medical Journal of Australia

Volumn 201, Issue 10, 2014, Pages 596-600

  Wood, Nicholas J ^a   Blyth, Chris C ^b   Willis, Gabriela A ^c   Richmond, Peter ^b   Gold, Michael S ^d   Buttery, Jim P ^e   Crawford, Nigel ^f   Crampton, Michael ^g   Yin, J Kevin ^a   Chow, Maria Yui Kwan ^a   Macartney, Kristine ^a  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^b PRINCESS MARGARET HOSPITAL FOR CHILDREN   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d UNIVERSITY OF ADELAIDE   (Australia)

^e MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^f ROYAL CHILDREN'S HOSPITAL   (Australia)

^g South Western Sydney Medicare Local   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; INACTIVATED VACCINE;

ARTICLE; AUSTRALIA; CHILD; DOSE RESPONSE; DRUG SAFETY; ERYTHEMA; FATIGUE; FEBRILE CONVULSION; FEMALE; FEVER; HEADACHE; HUMAN; INFANT; INFLUENZA; INFLUENZA VACCINATION; INJECTION SITE PAIN; INJECTION SITE SWELLING; MAJOR CLINICAL STUDY; MALE; NAUSEA; NAUSEA AND VOMITING; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PROSPECTIVE STUDY; RASH; RIGOR; SAMPLE SIZE; SCHOOL CHILD; HEALTH SURVEY; PATIENT SAFETY; RISK ASSESSMENT;

AUSTRALIA; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; INFLUENZA VACCINES; MALE; PATIENT SAFETY; POPULATION SURVEILLANCE; RISK ASSESSMENT; VACCINES, INACTIVATED;

EID: 84925547919     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/mja13.00097     Document Type: Article

References (26)

1. Therapeutic Goods Administration. Investigation into febrile reactions in young children following 2010 seasonal trivalent infl uenza vaccination. Status report as at 2 July 2010 (updated 24 September 2010). http://www.tga.gov.au/safety/alerts-medicineseasonal-flu-100702.htm (accessed Jul 2014).
2. Armstrong PK, Dowse GK, Effl er PV, et al. Epidemiological study of severe febrile reactions in young children in Western Australia caused by a 2010 trivalent inactivated infl uenza vaccine. BMJ Open 2011; 1: e000016.
3. Australian Technical Advisory Group on Immunisation (ATAGI), Therapeutic Goods Administration (TGA) Joint Working Group. Analysis of febrile convulsions following immunisation in children following monovalent pandemic H1N1 vaccine (Panvax/Panvax Junior, CSL). 2010. http://www.tga.gov.au/safety/alerts-medicine-seasonal-flu-100928.htm (accessed Jul 2014).
4. Kelly H, Carcione D, Dowse G, Effler P. Quantifying benefits and risks of vaccinating Australian children aged six months to four years with trivalent inactivated seasonal infl uenza vaccine in 2010. Euro Surveill 2010; 15: 19661.
5. Gold MS, Effl er P, Kelly H, et al. Febrile convulsions after 2010 seasonal trivalent infl uenza vaccine: implications for vaccine safety surveillance in Australia. Med J Aust 2010; 193: 492-493.
6. Wood N, Sheppeard V, Cashman P, et al. Infl uenza vaccine safety in children less than 5 years old: the 2010 and 2011 experience in Australia. Pediatr Infect Dis J 2012; 31: 199-202.
7. Rockman S, Dyson A, Koernig S, et al. Evaluation of the bioactivity of influenza vaccine strains in vitro suggests that the introduction of new strains in the 2010 southern hemisphere trivalent infl uenza vaccine is associated with adverse events. Vaccine 2014; 32: 3861-3868.
8. Rockman S, Becher D, Dyson A, et al. Role of viral RNA and lipid in the adverse events associated with the 2010 southern hemisphere trivalent influenza vaccine. Vaccine 2014; 32: 3869-3876.
9. Petousis-Harris H, Poole T, Turner N, Reynolds G. Febrile events including convulsions following the administration of four brands of 2010 and 2011 inactivated seasonal infl uenza vaccine in NZ infants and children: the importance of routine active safety surveillance. Vaccine 2012; 30: 4945-4952.
10. Department of Health. Seasonal flu vaccine and young children. 2010. http://www.health.gov.au/internet/main/publishing.nsf/Content/mr-yr10-dept-dept230410.htm (accessed Jul 2014).
11. Therapeutic Goods Administration. Seasonal infl uenza vaccines. Safety advisory. 2011. http://www.tga.gov.au/safety/alerts-medicineseasonal-flu-110310.htm (accessed Jul 2014).
12. Blyth CC, Jacoby P, Effl er PV, et al. Eff ectiveness of trivalent fl u vaccine in healthy young children. Pediatrics 2014; 133: e1218-e1225.
13. Horvath J. Review of the management of adverse events associated with Panvax and Fluvax. Canberra: Department of Health and Ageing, 2011. http://www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/adverse-event (accessed Aug 2014).
14. Australian Technical Advisory Group on Immunisation. The Australian immunisation handbook. 10th ed. Canberra: Department of Health and Ageing, 2013. http://www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/Handbook10-home (accessed Aug 2014).
15. Australian Technical Advisory Group on Immunisation (ATAGI). Clinical advice for immunisation providers regarding the administration of 2014 seasonal infl uenza vaccines – March 2014. http://www.immunise.health.gov.au/internet/immunise/Publishing.nsf/content/ATAGI-advice-TIV (accessed Jul 2014).
16. Kaczmarek MC, Duong UT, Ware RS, et al. The risk of fever following one dose of trivalent inactivated infl uenza vaccine in children aged ³ 6 months to <36 months: a comparison of published and unpublished studies. Vaccine 2013; 31: 5359-5365.
17. Li-Kim-Moy J, Yin JK, Rashid H, et al. Systematic review on adverse events following trivalent seasonal infl uenza vaccination (TIV) in children. Presented at: The 31st Meeting of the European Society for Paediatric Infectious Diseases (ESPID 2013); 2013 May 6–17; Milan, Italy.
18. Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap) – a metadata-driven methodology and workfl ow process for providing translational research informatics support. J Biomed Inform 2009; 42: 377-381.
19. Blyth CC, Markus TY, Effler PV, Richmond PC. Ensuring safety of the 2011 trivalent infl uenza vaccine in young children [letter]. Med J Aust 2011; 195: 52.
20. Lambert SB, Chuk LM, Nissen MD, et al. Safety and tolerability of a 2009 trivalent inactivated split-virion infl uenza vaccine in infants, children and adolescents. Infl uenza Other Respir Viruses 2013; 7: 676-685.
21. Stockwell MS, Broder K, LaRussa P, et al. Risk of fever after pediatric trivalent inactivated infl uenza vaccine and 13-valent pneumococcal conjugate vaccine. JAMA Pediatr 2014; 168: 211-219.
22. Tse A, Tseng HF, Greene SK, et al. Signal identifi cation and evaluation for risk of febrile seizures in children following trivalent inactivated infl uenza vaccine in the Vaccine Safety Datalink Project, 2010-2011. Vaccine 2012; 30: 2024-2031.
23. Cashman P, Dalton C, Wood N, et al. VAXTRACKER: online near real-time surveillance of adverse events after influenza vaccination in children. Presented at: Communicable Disease Control conference 2013; 2013 March 20–23; Canberra, Australia.
24. Leeb A, Regan AK, Peters IJ, et al. Using automated text messages to monitor adverse events following immunisation in general practice. Med J Aust 2014; 200: 416-418.
25. Regan AK, Blyth CC, Effler PV. Using SMS technology to verify the safety of seasonal trivalent infl uenza vaccine for pregnant women in real time. Med J Aust 2013; 199: 744-746.
26. National Centre for Immunisation Research and Surveillance. Overview of AusVaxSafety. 2014. http://www.ncirs.edu.au/surveillance/ausvaxsafety/index.php (accessed Jul 2014).